Tabulated list of adverse reactions: There are adverse reactions that appear twice in the table, as the estimated frequencies differ between indications. (See table.)

Safety related to method of administration: Based on results from a dedicated randomised controlled multicentre trial, administration of terlipressin as continuous IV infusion may be associated with lower rates of severe adverse events than with administration by IV bolus (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
View ADR Reporting Link